Cargando…

Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers

In vivo gold standard for the ante-mortem assessment of brain β-amyloid pathology is currently β-amyloid positron emission tomography or cerebrospinal fluid measures of β-amyloid(42) or the β-amyloid(42)/β-amyloid(40) ratio. The widespread acceptance of a biomarker classification scheme for the Alzh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tosun, Duygu, Veitch, Dallas, Aisen, Paul, Jack, Clifford R, Jagust, William J, Petersen, Ronald C, Saykin, Andrew J, Bollinger, James, Ovod, Vitaliy, Mawuenyega, Kwasi G, Bateman, Randall J, Shaw, Leslie M, Trojanowski, John Q, Blennow, Kaj, Zetterberg, Henrik, Weiner, Michael W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023542/ https://www.ncbi.nlm.nih.gov/pubmed/33842885 http://dx.doi.org/10.1093/braincomms/fcab008

Ejemplares similares

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease
por: Veitch, Dallas P., et al.
Publicado: (2021)

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report
por: Weiner, Michael W., et al.
Publicado: (2017)

Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4
por: Weiner, Michael W., et al.
Publicado: (2022)

Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer’s disease in veterans, using the Alzheimer’s Disease Neuroimaging Initiative
por: Weiner, Michael W., et al.
Publicado: (2014)

A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans
por: Hölttä, Mikko, et al.
Publicado: (2016)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2014)

Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial
por: Delrieu, Julien, et al.
Publicado: (2023)

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2021)

Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease
por: Nho, Kwangsik, et al.
Publicado: (2017)

The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review
por: Brand, Abby L., et al.
Publicado: (2022)

Biomarkers for tau pathology
por: Schöll, Michael, et al.
Publicado: (2019)

The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives
por: Weber, Christopher J., et al.
Publicado: (2021)

The global Alzheimer's Association round robin study on plasma amyloid β methods
por: Pannee, Josef, et al.
Publicado: (2021)

The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI)
por: Risacher, Shannon L., et al.
Publicado: (2013)

Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures
por: Mielke, Michelle M., et al.
Publicado: (2019)

Diurnal Patterns of Soluble Amyloid Precursor Protein Metabolites in the Human Central Nervous System
por: Dobrowolska, Justyna A., et al.
Publicado: (2014)

How Will Aducanumab Approval Impact AD Research?
por: Weiner, Michael W., et al.
Publicado: (2021)

Q & A: The Alzheimer's disease neuroimaging initiative
por: Aisen, Paul S
Publicado: (2011)

CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders
por: Mattsson, N, et al.
Publicado: (2013)

Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort
por: Swaminathan, Shanker, et al.
Publicado: (2011)

Diagnostic utility of ASL‐MRI and FDG‐PET in the behavioral variant of FTD and AD
por: Tosun, Duygu, et al.
Publicado: (2016)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology
por: Laforce, Robert, et al.
Publicado: (2014)

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
por: Palmqvist, Sebastian, et al.
Publicado: (2017)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative
por: Zettergren, Anna, et al.
Publicado: (2021)

Mild Cognitive Impairment Staging Yields Genetic Susceptibility, Biomarker, and Neuroimaging Differences
por: Moore, Elizabeth E., et al.
Publicado: (2020)

Network‐wise concordance of multimodal neuroimaging features across the Alzheimer's disease continuum
por: Stocks, Jane, et al.
Publicado: (2022)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
por: Andreasson, Ulf, et al.
Publicado: (2016)

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease
por: Insel, Philip S, et al.
Publicado: (2015)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions
por: Simrén, Joel, et al.
Publicado: (2021)

Deep Learning in Alzheimer's Disease: Diagnostic Classification and Prognostic Prediction Using Neuroimaging Data
por: Jo, Taeho, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qt4m566oc1uj6g8avlnqlgapi1